# Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

> **NCT00328601** · PHASE3 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 170 (—)

## Conditions studied

- Diabetic Polyneuropathy

## Interventions

- **DRUG:** Thioctic Acid

## Key facts

- **NCT ID:** NCT00328601
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 170 (—)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328601, "Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00328601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*